← All trials
NCT06282575
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 19, 2024
- Primary completion
- Jul 1, 2028
- Completion date
- Nov 1, 2029
- First posted
- Feb 28, 2024
- Last posted
- Nov 12, 2024
- Enrollment
- 286
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jazz PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.